White Paper: EMA’s 2017 FIH Guidelines. 5 years on and the Impact on Early Phase Clinical Studies
AC-Impact-of-EMAs-guidelines-on-FIH-studies-2022-White-Paper-Download
AC Celebration our First 2 Years
Armstrong Clinical has now completed its first 2 years of operations. Although these two year have been during challenging time,…
Orphan Disease Clinical Development:
Overcoming the Challenges Through Effective Clinical Study Design When developing novel therapies targeting rare diseases, a departure from classical development strategies…
“Haplomind” Big data analytics, Biology and Machine Learning to help treat Perinatal Depression.
We sit down with Haplomind founder Dr. Sonali Mohanty Quantius to understand more about Haplomind and its use in the…
Brad Joblin from Armstrong Clinical invited as Guest Speaker to the AGM of the HSP Research Foundation
Bradley Joblin from Armstrong Clinical has been invited to be the guest speaker at the AGM of HSP Research Foundation.…
Agreement Between Armstrong Clinical and MyMedical to Provide Comprehensive Clinical Trial, Clinical Development and Commercial Support Services to Biotech, Medtech and Pharmaceutical Industry Clients.
Melbourne (Australia) - 4th August 2020: Armstrong Clinical, specialists in clinical development strategy, early phase clinical study design, pricing and regulatory strategy…
Biotech Commercialisation. Why an Accurate Clinical Development Forecast is Necessary Early in Drug Development
The aim for many biotech companies taking a discovery into clinical development will be to generate data from phase 1…
Continuing Non-Clinical Evidence Generation Throughout Drug Development:
Important goals of pre-clinical drug development programs (in silico, in vivo, in vitro studies) include the formulation of precise estimates…
Australian Clinical Trial Governance Framework Project
Clinical trials bring in more than $1.1 billion per year to the Australian R&D economy. More importantly, they provide access to…